↓ Skip to main content

Efficacy and Safety of 225Ac-PSMA-617-Targeted Alpha Therapy in Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis

Overview of attention for article published in Frontiers in oncology, February 2022
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
2 X users

Citations

dimensions_citation
40 Dimensions

Readers on

mendeley
48 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Efficacy and Safety of 225Ac-PSMA-617-Targeted Alpha Therapy in Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
Published in
Frontiers in oncology, February 2022
DOI 10.3389/fonc.2022.796657
Pubmed ID
Authors

Jiao Ma, Lanying Li, Taiping Liao, Weidong Gong, Chunyin Zhang

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 48 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 48 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 6 13%
Student > Ph. D. Student 5 10%
Student > Master 4 8%
Student > Bachelor 2 4%
Student > Doctoral Student 2 4%
Other 6 13%
Unknown 23 48%
Readers by discipline Count As %
Medicine and Dentistry 9 19%
Physics and Astronomy 5 10%
Chemistry 3 6%
Biochemistry, Genetics and Molecular Biology 1 2%
Unspecified 1 2%
Other 2 4%
Unknown 27 56%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 February 2022.
All research outputs
#21,381,945
of 26,246,850 outputs
Outputs from Frontiers in oncology
#11,785
of 22,949 outputs
Outputs of similar age
#403,657
of 533,328 outputs
Outputs of similar age from Frontiers in oncology
#707
of 1,453 outputs
Altmetric has tracked 26,246,850 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 22,949 research outputs from this source. They receive a mean Attention Score of 3.2. This one is in the 27th percentile – i.e., 27% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 533,328 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 14th percentile – i.e., 14% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 1,453 others from the same source and published within six weeks on either side of this one. This one is in the 37th percentile – i.e., 37% of its contemporaries scored the same or lower than it.